Testing SSGJ-612 for advanced solid tumors with HER2
Part of Cancer clinical trials.
This trial tests a new drug called SSGJ-612 for people with advanced solid tumors that have stopped responding to standard treatments. It is specifically for patients whose tumors have a protein called HER2, and it aims to see if the drug can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your cancer is advanced and has come back or spread, and standard treatments have stopped working or are not available.
- Your tumor tests positive for HER2 (a protein that helps some cancers grow).
- You have at least one tumor that can be measured on a scan and is suitable for repeat measurements.
- You are in good enough physical condition to be up and about (ECOG score 0 or 1).
- You do not have active cancer spread to the brain, fluid buildup needing frequent drainage, or a weak immune system (like HIV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SSGJ-709 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
This trial tests two new antibody drugs (SSGJ-705 and SSGJ-612), alone or combined with chemotherapy, in patients with advanced cancers that have a protein called HER2. The study aims to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of two targeted medicines for people with a certain type of advanced breast cancer that has grown despite hormone therapy. The medicines may help shrink tumors and slow the cancer's growth.
This phase 1 trial tests a new targeted drug (SSGJ-705) for people with advanced solid tumors or lymphomas. Doctors will check safety and find the best dose, and there may be a chance the drug helps shrink or control the cancer.
This trial tests an investigational drug (SHR-4602) alone or with other treatments for advanced solid tumors that have HER2. The goal is to see if it can shrink or control the cancer.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.